|
1
|
Lugowska I, Mierzejewska E, Lenarcik M,
Klepacka T, Koch I, Michalak E and Szamotulska K: The clinical
significance of changes in ezrin expression in osteosarcoma of
children and young adults. Tumour Biol. 37:12071–12078. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee JA, Jeon DG, Cho WH, Song WS, Yoon HS,
Park HJ, Park BK, Choi HS, Ahn HS, Lee JW, et al: Higher
gemcitabine dose was associated with better outcome of osteosarcoma
patients receiving gemcitabine-docetaxel chemotherapy. Pediatr
Blood Cancer. 63:1552–1556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang H, Liu W, Li G, Fan T and Mao B:
Chinese medicinal herbs in the treatment of upper airway cough
syndrome: A systematic review of randomized, controlled trials.
Altern Ther Health Med. 22:38–51. 2016.PubMed/NCBI
|
|
4
|
Wang L, Yang L, Lu Y, Chen Y, Liu T, Peng
Y, Zhou Y, Cao Y, Bi Z, Liu T, et al: Osthole induces cell cycle
arrest and inhibits migration and invasion via PTEN/Akt pathways in
osteosarcoma. Cell Physiol Biochem. 38:2173–2182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ali Gumustas S, Isyar M, Topuk S, Yilmaz
I, Oznam K, Onay T, Ofluoglu O and Mahirogullari M: Systematic
evaluation of drug-loaded hydrogels for application in osteosarcoma
treatment. Curr Pharm Biotechnol. 17:866–872. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kebudi R, Ozger H, Kızılocak H, Bay SB and
Bilgiç B: Osteosarcoma after hematopoietic stem cell
transplantation in children and adolescents: Case Report and Review
of the Literature. Pediatr Blood Cancer. 63:1664–1666. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng L, Wang C and Jing J: Cell cycle
kinases in osteosarcoma: Potential for therapeutic intervention.
Curr Pharm Des. 22:4830–4834. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maximov VV and Aqeilan RI: Genetic factors
conferring metastasis in osteosarcoma. Future Oncol. 12:1623–1644.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X, Zhang Y, Wan S, Li H, Li D, Xia J,
Yuan Z, Ren M, Yu S, Li S, et al: A comparative study between
limb-salvage and amputation for treating osteosarcoma. J Bone
Oncol. 5:15–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wan J and Zhang X, Liu T and Zhang X:
Strategies and developments of immunotherapies in osteosarcoma.
Oncol Lett. 11:511–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Durham BH, Diamond EL and Abdel-Wahab O:
Histiocytic neoplasms in the era of personalized genomic medicine.
Curr Opin Hematol. 23:416–425. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cagle PT, Raparia K and Portier BP:
Emerging biomarkers in personalized therapy of lung cancer. Adv Exp
Med Biol. 890:25–36. 2016. View Article : Google Scholar
|
|
13
|
Krishna A, Singh S, Kumar V and Pal US:
Molecular concept in human oral cancer. Natl J Maxillofac Surg.
6:9–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De P, Carlson JH, Leyland-Jones B and Dey
N: Role of 'oncogenic nexus' of CIP2A in breast oncogenesis: How
does it work? Am J Cancer Res. 5:2872–2891. 2015.
|
|
15
|
Luo Z, Zhang X, Zeng W, Su J, Yang K, Lu
L, Lim CB, Tang W, Wu L, Zhao S, et al: TRAF6 regulates melanoma
invasion and metastasis through ubiquitination of Basigin.
Oncotarget. 7:7179–7192. 2016.PubMed/NCBI
|
|
16
|
Han F, Zhang L, Qiu W and Yi X: TRAF6
promotes the invasion and metastasis and predicts a poor prognosis
in gastric cancer. Pathol Res Pract. 212:31–37. 2016. View Article : Google Scholar
|
|
17
|
Lin FT, Lin VY, Lin VT and Lin WC: TRIP6
antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the
LPA2 receptor-mediated TRAF6 activation. Cell Discov. 2:150482016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao T, Tang X, Umeshappa CS, Ma H, Gao H,
Deng Y, Freywald A and Xiang J: Simulated microgravity promotes
cell apoptosis through suppressing Uev1A/TICAM/TRAF/NF-κB-regulated
anti-apoptosis and p53/PCNA- and ATM/ATR-Chk1/2-controlled
DNA-damage response pathways. J Cell Biochem. 117:2138–2148. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Panda S, Nilsson JA and Gekara NO:
Deubiquitinase MYSM1 regulates innate immunity through inactivation
of TRAF3 and TRAF6 complexes. Immunity. 43:647–659. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tomomura M, Suzuki R, Shirataki Y,
Sakagami H, Tamura N, Tomomura A and Rhinacanthin C: Rhinacanthin C
inhibits osteoclast differentiation and bone resorption: Roles of
TRAF6/TAK1/MAPKs/NF-κB/NFATc1 signaling. PLoS One. 10:e01301742015.
View Article : Google Scholar
|
|
21
|
Kong X, Yang Y, Wu W, Wan H, Li X, Zhong
M, Su X, Jia S and Lin N: Triterpenoid saponin W3 from Anemone
flaccida suppresses osteoclast differentiation through inhibiting
activation of MAPKs and NF-κB pathways. Int J Biol Sci.
11:1204–1214. 2015. View Article : Google Scholar :
|
|
22
|
Kong X, Wu W, Yang Y, Wan H, Li X, Zhong
M, Zhao H, Su X, Jia S, Ju D, et al: Total saponin from Anemone
flaccida Fr. Schmidt abrogates osteoclast differentiation and bone
resorption via the inhibition of RANKL-induced NF-κB, JNK and p38
MAPKs activation. J Transl Med. 13:912015. View Article : Google Scholar
|
|
23
|
He Z, Huang C, Lin G and Ye Y:
siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits
the invasion of human lung cancer SPC-A1 cells. Oncol Rep.
35:1933–1940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peng Z, Shuangzhu Y, Yongjie J, Xinjun Z
and Ying L: Retraction note to: TNF receptor-associated factor 6
regulates proliferation, apoptosis, and invasion of glioma cells.
Mol Cell Biochem. 415:2072016. View Article : Google Scholar
|
|
25
|
Han Q, Yao F, Zhong C and Zhao H: TRAF6
promoted the metastasis of esophageal squamous cell carcinoma.
Tumour Biol. 35:715–721. 2014. View Article : Google Scholar
|
|
26
|
Sun H, Li XB, Meng Y, Fan L, Li M and Fang
J: TRAF6 upregulates expression of HIF-1α and promotes tumor
angiogenesis. Cancer Res. 73:4950–4959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meng Q, Zheng M, Liu H, Song C, Zhang W,
Yan J, Qin L and Liu X: TRAF6 regulates proliferation, apoptosis,
and invasion of osteosarcoma cell. Mol Cell Biochem. 371:177–186.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peng S, Gao D, Gao C, Wei P, Niu M and
Shuai C: MicroRNAs regulate signaling pathways in osteogenic
differentiation of mesenchymal stem cells (Review). Mol Med Rep.
14:623–629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh CH, Moles R and Nicot C: Clinical
significance of microRNAs in chronic and acute human leukemia. Mol
Cancer. 15:372016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng T, Shao F, Wu Q, Zhang X, Xu D, Qian
K, Xie Y, Wang S, Xu N, Wang Y, et al: miR-124 downregulation leads
to breast cancer progression via LncRNA-MALAT1 regulation and
CDK4/E2F1 signal activation. Oncotarget. 7:16205–16216.
2016.PubMed/NCBI
|
|
31
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124
inhibits the migration and invasion of ovarian cancer cells by
targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Denduluri SK, Wang Z, Yan Z, Wang J, Wei
Q, Mohammed MK, Haydon RC, Luu HH and He TC: Molecular pathogenesis
and therapeutic strategies of human osteosarcoma. J Biomed Res. Aug
30–2015.Epub ahead of print. PubMed/NCBI
|
|
33
|
Gu X, Ding J, Zhang Z, Li Q, Zhuang X and
Chen X: Polymeric nanocarriers for drugdelivery in osteosarcoma
treatment. Curr Pharm Des. 21:5187–5197. 2015. View Article : Google Scholar
|
|
34
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lim HJ and Yang JL: Regulatory roles and
therapeutic potential of microRNA in sarcoma. Crit Rev Oncol
Hematol. 97:118–130. 2016. View Article : Google Scholar
|
|
36
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: Emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu H, Tamashiro S, Baritaki S, Penichet
M, Yu Y, Chen H, Berenson J and Bonavida B: TRAF6 activation in
multiple myeloma: A potential therapeutic target. Clin Lymphoma
Myeloma Leuk. 12:155–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kumar A, Bhatnagar S and Paul PK: TWEAK
and TRAF6 regulate skeletal muscle atrophy. Curr Opin Clin Nutr
Metab Care. 15:233–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Landström M: The TAK1-TRAF6 signalling
pathway. Int J Biochem Cell Biol. 42:585–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yan J, Yin Y, Zhong W, Wang C and Wang Z:
CD137 Regulates NFATc1 expression in mouse VSMCs through
TRAF6/NF-kappaB p65 signaling pathway. Mediators Inflamm.
2015:6397802015. View Article : Google Scholar
|
|
42
|
Shi Z, Zhang Z, Zhang Z, Wang Y, Li C,
Wang X, He F, Sun L, Jiao S, Shi W, et al: Structural Insights into
mitochondrial antiviral signaling protein (MAVS)-tumor necrosis
factor receptor-associated factor 6 (TRAF6) signaling. J Biol Chem.
290:26811–26820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tian X and Zhang X: A single nucleotide
polymorphism (rs1056629) in 3′-UTR of MMP-9 is responsible for a
decreased risk of metastatic osteosarcoma by compromising its
interaction with microRNA-491-5p. Cell Physiol Biochem.
38:1415–1424. 2016. View Article : Google Scholar
|
|
44
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu S, Du X, Wu M, Du H, Shi X and Zhang T:
MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion
by targeting catenin-δ1. Gene. 584:83–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bhattacharya S, Chalk AM, Ng AJ, Martin
TJ, Zannettino AC, Purton LE, Lu J, Baker EK and Walkley CR:
Increased miR-155-5p and reduced miR-148a-3p contribute to the
suppression of osteosarcoma cell death. Oncogene. 35:5282–5294.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pu Y, Zhao F, Cai W, Meng X, Li Y and Cai
S: MiR-193a-3p and miR-193a-5p suppress the metastasis of human
osteosarcoma cells by downregulating Rab27B and SRR, respectively.
Clin Exp Metastasis. 33:359–372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhou L, Xu Z, Ren X, Chen K and Xin S:
MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and
invasion in colorectal cancer by downregulating Rho-associated
protein kinase 1 (ROCK1). Cell Physiol Biochem. 38:1785–1795. 2016.
View Article : Google Scholar
|
|
49
|
Deng D, Wang L, Chen Y, Li B, Xue L, Shao
N, Wang Q, Xia X, Yang Y and Zhi F: miR-124-3p regulates cell
proliferation, invasion, apoptosis and bioenergetics by targeting
PIM1 in astrocytoma. Cancer Sci. 107:899–907. 2016. View Article : Google Scholar : PubMed/NCBI
|
